Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 7/20 | 0.73 |
| ▸ | CPT2 | P23786 | 2/20 | 0.38 |
| ▸ | CPT1A | P50416 | 2/20 | 0.38 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20489456 | 1.00 | AADAT (0.73) | AADATCPT2CPT1ACPT1BTRPV1 | |
| SCHEMBL20489687 | 0.86 | AADAT (0.62) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL20489689 | 0.86 | AADAT (0.62) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL20489418 | 0.85 | AADAT (1.00) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL20489417 | 0.85 | AADAT (1.00) | AADATCPT2CPT1ACPT1B | |
| SCHEMBL21206590 | 0.85 | AADAT (1.00) | AADAT | |
| SCHEMBL20489413 | 0.82 | AADAT (0.52) | AADATCPT2CPT1ACPT1BTRPV1 | |
| SCHEMBL20489411 | 0.82 | AADAT (0.52) | AADATCPT2CPT1ACPT1BTRPV1 | |
| SCHEMBL21206843 | 0.82 | AADAT (0.75) | AADAT | |
| SCHEMBL20489568 | 0.82 | AADAT (0.75) | AADATHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | AADAT 1539/4885CPT2 419/4885CPT1A 298/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | AADAT 1329/4885CPT2 354/4885CPT1A 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.